OAKLAND, Calif., March 4, 2021 -- Koya Medical (“Koya”), a medical technology company advancing evidence-based therapies for vascular disease, today announced the appointment of Ali Bauerlein to its Board of Directors.
Ms. Bauerlein brings more than 20 years of experience in the medical technology space as the CFO and co-founder of Inogen, Inc. (INGN), a leading respiratory technology provider. “I am honored to help the Koya Medical team in their mission to improve the lives of patients suffering from chronic lymphedema and venous diseases,” said Ms. Bauerlein. “I believe Koya can be a leader in this market with their patient-driven design and innovative technology.”
“We are excited to have a seasoned leader in medical innovations and home health join our team,” said Andy Doraiswamy, PhD, CEO, Koya Medical. “Ali is an experienced executive with a strong history of building shareholder value in the healthcare domain,” said Josh Baltzell, Chairman/Board Director at Koya Medical.
Koya Medical received FDA-clearance for the Dayspring™ system, a prescription only mobile active compression system for the treatment of lymphedema and venous insufficiency. Dayspring is the first digitally connected system with an FDA cleared label enabling patient mobility during use.
About Koya Medical
Founded in 2018 and headquartered in Dallas, Koya Medical is a medical technology company developing a portfolio of evidence-based treatments designed to improve clinical outcomes and patient experience in vascular disease.
